The etiology of endocrine therapy resistance in estrogen receptor-positive (ER+) breast cancer is complex (Ma et al., 2015) but includes acquired somatic mutations within the ligand-binding domain (LBD) of the estrogen receptor gene (ESR1) causing ligand-independent activation (Pejerrey et al., 2018). The gene discussed is ESR1; the disease is breast cancer.